Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Go back to Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 50.02 -0.61 (1.2%)
Previous Close $50.63    52 Week High $45.58 
Open $50.19    52 Week Low $37.82 
Day High $50.45    P/E N/A 
Day Low $49.91    EPS $0.00 
Volume 3,614,140       

GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 50.02 -0.61 (1.2%)
Previous Close $50.63    52 Week High $45.58 
Open $50.19    52 Week Low $37.82 
Day High $50.45    P/E N/A 
Day Low $49.91    EPS $0.00 
Volume 3,614,140       

Pfizer Inc. (NYSE: PFE) Delayed: 29.85 -0.26 (0.86%)
Previous Close $30.11    52 Week High $37.39 
Open $30.00    52 Week Low $28.25 
Day High $30.09    P/E 18.09 
Day Low $29.69    EPS $1.65 
Volume 22,211,433